HRP20190491T1 - Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti - Google Patents

Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti

Info

Publication number
HRP20190491T1
HRP20190491T1 HRP20190491TT HRP20190491T HRP20190491T1 HR P20190491 T1 HRP20190491 T1 HR P20190491T1 HR P20190491T T HRP20190491T T HR P20190491TT HR P20190491 T HRP20190491 T HR P20190491T HR P20190491 T1 HRP20190491 T1 HR P20190491T1
Authority
HR
Croatia
Prior art keywords
arylcarbonyl
oxy
treatment
neurodegenerative diseases
compounds useful
Prior art date
Application number
HRP20190491TT
Other languages
English (en)
Inventor
Tatsuki Koike
Masato Yoshikawa
Haruhi ANDO
William John FARNABY
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143241&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190491(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20190491T1 publication Critical patent/HRP20190491T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20190491TT 2011-10-07 2019-03-12 Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti HRP20190491T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011222741 2011-10-07
PCT/JP2012/076257 WO2013054822A1 (en) 2011-10-07 2012-10-03 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
EP12781479.6A EP2763979B1 (en) 2011-10-07 2012-10-03 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
HRP20190491T1 true HRP20190491T1 (hr) 2019-05-03

Family

ID=47143241

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190491TT HRP20190491T1 (hr) 2011-10-07 2019-03-12 Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti

Country Status (41)

Country Link
US (11) US9193709B2 (hr)
EP (1) EP2763979B1 (hr)
JP (1) JP6117191B2 (hr)
KR (1) KR101967497B1 (hr)
CN (1) CN103842356B (hr)
AP (1) AP2014007606A0 (hr)
AR (1) AR088226A1 (hr)
AU (1) AU2012321815B2 (hr)
BR (2) BR122022001219B1 (hr)
CA (1) CA2851087C (hr)
CL (1) CL2014000806A1 (hr)
CO (1) CO6940432A2 (hr)
CR (1) CR20140151A (hr)
CY (1) CY1121549T1 (hr)
DK (1) DK2763979T3 (hr)
DO (1) DOP2014000064A (hr)
EA (1) EA025662B1 (hr)
EC (1) ECSP14013329A (hr)
ES (1) ES2716531T3 (hr)
GE (1) GEP201706608B (hr)
HR (1) HRP20190491T1 (hr)
HU (1) HUE043171T2 (hr)
IL (1) IL231678A (hr)
LT (1) LT2763979T (hr)
MA (1) MA35623B1 (hr)
ME (1) ME03372B (hr)
MX (1) MX360706B (hr)
MY (1) MY176126A (hr)
PE (1) PE20141120A1 (hr)
PL (1) PL2763979T3 (hr)
PT (1) PT2763979T (hr)
RS (1) RS58470B1 (hr)
SG (1) SG2014010417A (hr)
SI (1) SI2763979T1 (hr)
TN (1) TN2014000122A1 (hr)
TR (1) TR201902788T4 (hr)
TW (1) TWI582084B (hr)
UA (1) UA115133C2 (hr)
UY (1) UY34365A (hr)
WO (1) WO2013054822A1 (hr)
ZA (1) ZA201402424B (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842356B (zh) 2011-10-07 2017-03-15 武田药品工业株式会社 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
CR20150364A (es) 2012-12-11 2016-09-20 Takeda Pharmaceuticals Co Compuesto heterociclico
BR112015022174B1 (pt) 2013-03-13 2022-07-05 Sage Therapeutics, Inc Compostos esteróides neuroativos, sua composição farmacêutica e seu uso
US9598398B2 (en) 2013-04-04 2017-03-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9624184B2 (en) 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3152198B1 (en) 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
ES2884086T3 (es) 2015-07-06 2021-12-10 Sage Therapeutics Inc Oxisteroles y sus procedimientos de uso
WO2017065287A1 (ja) * 2015-10-16 2017-04-20 武田薬品工業株式会社 複素環化合物の製造方法
GB201604029D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109071440A (zh) * 2016-05-13 2018-12-21 日产化学株式会社 2-乙酰基吡啶化合物的制造方法
AU2017337121B2 (en) 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
JP7196157B2 (ja) * 2017-08-31 2022-12-26 武田薬品工業株式会社 Cns状態の治療
WO2020027344A1 (en) 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
WO2020059894A1 (en) 2018-09-20 2020-03-26 Takeda Pharmaceutical Company Limited CH24H Inhibitors For Pain Use
JP7189749B2 (ja) 2018-12-04 2022-12-14 株式会社日立産機システム スクリュー圧縮機
TW202110824A (zh) * 2019-05-24 2021-03-16 美商賽吉醫療公司 化合物、組合物及使用方法
WO2022115620A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
WO2022261510A1 (en) 2021-06-11 2022-12-15 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
US6545127B1 (en) 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2002064558A2 (en) 2001-02-14 2002-08-22 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
EP1390353A1 (en) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
GT200500375A (es) 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
JPWO2006137465A1 (ja) 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
KR101124156B1 (ko) 2005-11-30 2012-03-23 에프. 호프만-라 로슈 아게 1,5-치환된 인돌-2-일 아마이드 유도체
AR058567A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Formulaciones de proteinas estables
WO2008011453A2 (en) 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
WO2008134547A1 (en) * 2007-04-25 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions
WO2008153722A1 (en) 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
RS54413B1 (en) 2008-08-22 2016-04-28 Sanofi [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
JP5316468B2 (ja) 2010-04-09 2013-10-16 株式会社豊田自動織機 リアクトル構造
MY165584A (en) 2010-07-29 2018-04-05 Rigel Pharmaceuticals Inc Ampk-activating heterocyclic compounds and methods for using the same
CN104906103B (zh) 2010-12-14 2018-05-18 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
CN103842356B (zh) * 2011-10-07 2017-03-15 武田药品工业株式会社 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物

Also Published As

Publication number Publication date
US20140228373A1 (en) 2014-08-14
TW201329068A (zh) 2013-07-16
US20140088118A1 (en) 2014-03-27
DOP2014000064A (es) 2014-07-15
KR20140072902A (ko) 2014-06-13
BR122022001219B1 (pt) 2023-03-14
US20170145031A1 (en) 2017-05-25
WO2013054822A1 (en) 2013-04-18
ECSP14013329A (es) 2014-05-31
BR112014007257B1 (pt) 2023-04-25
TR201902788T4 (tr) 2019-03-21
DK2763979T3 (en) 2019-04-01
CN103842356A (zh) 2014-06-04
NZ623185A (en) 2016-01-29
PL2763979T3 (pl) 2019-06-28
US8871766B2 (en) 2014-10-28
GEP201706608B (en) 2017-01-25
AU2012321815A1 (en) 2014-04-24
US20190071455A1 (en) 2019-03-07
CL2014000806A1 (es) 2014-09-05
CR20140151A (es) 2014-05-26
EA025662B1 (ru) 2017-01-30
US20150376205A1 (en) 2015-12-31
MA35623B1 (fr) 2014-11-01
US9586930B2 (en) 2017-03-07
TWI582084B (zh) 2017-05-11
ES2716531T3 (es) 2019-06-13
JP6117191B2 (ja) 2017-04-19
CA2851087C (en) 2019-09-24
ME03372B (me) 2020-01-20
CN103842356B (zh) 2017-03-15
US10144743B2 (en) 2018-12-04
AU2012321815B2 (en) 2017-03-09
EA201490747A1 (ru) 2014-08-29
PE20141120A1 (es) 2014-09-15
UA115133C2 (uk) 2017-09-25
UY34365A (es) 2013-05-31
AR088226A1 (es) 2014-05-21
EP2763979B1 (en) 2018-12-26
EP2763979A1 (en) 2014-08-13
RS58470B1 (sr) 2019-04-30
KR101967497B1 (ko) 2019-04-09
US20160326136A1 (en) 2016-11-10
US8648079B2 (en) 2014-02-11
AU2012321815A8 (en) 2014-06-12
US10550129B2 (en) 2020-02-04
TN2014000122A1 (en) 2015-07-01
US20130090341A1 (en) 2013-04-11
HUE043171T2 (hu) 2019-08-28
US9440990B2 (en) 2016-09-13
SI2763979T1 (sl) 2019-04-30
LT2763979T (lt) 2019-03-25
MX2014004253A (es) 2014-06-11
IL231678A (en) 2017-03-30
ZA201402424B (en) 2015-07-29
PT2763979T (pt) 2019-04-12
BR112014007257A2 (pt) 2017-03-28
US9193709B2 (en) 2015-11-24
IL231678A0 (en) 2014-05-28
MY176126A (en) 2020-07-24
CA2851087A1 (en) 2013-04-18
MX360706B (es) 2018-11-14
US20140088146A1 (en) 2014-03-27
CO6940432A2 (es) 2014-05-09
US10273245B2 (en) 2019-04-30
JP2014528904A (ja) 2014-10-30
US11174272B2 (en) 2021-11-16
AP2014007606A0 (en) 2014-05-31
SG2014010417A (en) 2014-06-27
US20190233436A1 (en) 2019-08-01
US10717748B2 (en) 2020-07-21
US8865717B2 (en) 2014-10-21
US20200157117A1 (en) 2020-05-21
US20210206781A1 (en) 2021-07-08
CY1121549T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
HK1197400A1 (zh) 治療 的化合物
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
HK1201256A1 (en) Pyrrolopyrimidine compounds for the treatment of cancer
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
AP3544A (en) Compounds for the treatment of addiction
HK1205502A1 (en) Compounds for the treatment of mtor pathway related diseases mtor
IL238592B (en) Compounds for the treatment of liver diseases
EP2739304A4 (en) PARTICLES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders
GB201106981D0 (en) Compounds for the treatment of clostridium difficle-associated disease